| Date/Time |
10/22 / 17:30 |
| Chg. / Chg.(%) |
7.80 / +2.31% |
| Bid |
342.10 / 100 |
| Ask |
345.10 / 30 |
| Open |
336.90 |
| Previous Close |
337.30 |
| High |
346.50 |
| Low |
335.00 |
| Volume [CHF] |
95,104,610.40 |
| Volume [Units] |
341,715 |
| Price fixings |
5763 |
| ISIN |
CH0013841017 |
| Security |
LONN |
| Exchange |
SIX Swiss Exchange |
| Type |
Stock |
- Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
10/17/2019 / 00:17 - GlobeNewswire
-
- Japan Respiratory Diseases, 2019: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis
10/10/2019 / 12:20 - GlobeNewswire
-
- Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
10/08/2019 / 08:00 - GlobeNewswire
-
- Vaccine Contract Manufacturing Market, 2030 - Market is Anticipated to Generate Revenues Worth USD 100 Billion by 2025
10/04/2019 / 10:05 - GlobeNewswire
-
- Global Viral Vector Manufacturing Market Analysis, Trends, and Forecasts 2019-2025
10/03/2019 / 11:10 - GlobeNewswire
Real-time